FEATURES OF THE VIRAL HEPATITIS C COURSE IN HIV-INFECTED PERSONS AND THEIR TREATMENT
DOI:
https://doi.org/10.11603/1681-2727.2018.4.9776Keywords:
HCV infection, HIV infection, combined infection, peculiarities of the course, treatmentAbstract
The aim of the study – based on the analysis of literary information to highlight the features of the course of viral hepatitis C in HIV-infected persons, as well as the basic principles of treatment of such patients and used drugs in the world and in Ukraine.
HIV and parenteral viral hepatitis refer to socially important diseases that can significantly affect the demographic situation in the country. Except the common ways and factors of transmission of viruses, the involvement of adolescents and young people to the epidemic process is the dominant factor that complicates the epidemiological situation with regard to HIV infection and parenteral viral hepatitis in Ukraine. The age factor is due to the phenomena of the current epidemic of drug addiction.
From the published data of a number of studies, the mutual influence of HIV and chronic viral hepatitis C on the course of both HIV-infection and chronic hepatitis C (CHC) is known. The incidence of AIDS and AIDS-related deaths is significantly higher in people with combined HCV / HIV infection, which is now a global public health problem.
The basic principles of treating patients with HCV in HIV-infected patients are consistent with those not infected with HIV. For the treatment of HCV-infection, current AASLD guidelines do not recommend interferon-based schemes anymore. Instead, nowadays the first-line treatment is considered to be oral antiviral agents of direct action. At the same time, interferon-containing treatment regimens are still used in Ukraine.
According to published results of a number of studies, the terminal stage of liver disease is a common cause of hospitalization and death of patients with combined HCV / HIV infection. But there are still controversial therapies for people with combined HIV and parenteral viral hepatitis. Therefore, the choice of optimal tactics for the management of such patients and the timely appointment of adequate treatment remains relevant.
References
WHO. (2017). Global Hepatitis Report. [E-resource]. Retrieved from: http://apps.who.int/iris/bitstream/handle/10665/255017/WHO-HIV-2017.06-eng.pdf;jsessionid=CA38A4EABD4E35A52C6364B08AA04D1C?sequence=1
Epidemichna sytuatsiia z VIL-infektsii v Ukraini [The epidemic situation with HIV in Ukraine. (November 27th 2017). [E-resource]. Retrieved from: http://moz.gov.ua/article/news/epidemichna-situacija-z-vil-infekcii-v-ukraini- [In Ukrainian].
(2016). VIL-infektsiia v Ukraini. Informatsiinyi biuleten. [HIV infection in Ukraine. Informational Bulletin]. Kyiv [in Ukrainian].
Hope, V.D., Eramova, I., Capurro, D., & Donoghoe, M.C. (2013). Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiology and Infection, 142 (2), 1-17.
MOZ Ukrainy Derzhavnyi Zaklad «Ukrainskyi tsentr z kontroliu ta monitorynhu zakhvoriuvan Ministerstva Okhorony Zdorovia Ukrainy». (2016). Pro stan zakhvoriuvanosti ta laboratornoi diahnostyky virusnykh hepatytiv B, C ta D v Ukraini u 2015 rotsi. 02.06.2016 r. № 04.5/877 [On the state of morbidity and laboratory diagnosis of viral hepatitis B, C and D in Ukraine in 2015.]. 02.06.2016 No. 04.5/877 [in Ukrainian].
(2017). Hepatyt C v Ukrani [Hepatitis C in Ukraine]. [E-resource]. Retrieved from: https://uk.wikipedia.org/wiki/%D0%93%D0%B5%D0%BF%D0%B0%D1%82%D0%B8%D1%82_C_%D0%B2_%D0%A3%D0%BA%D1%80%D0%B0%D1%97%D0%BD%D1%96#cite_note-hu-1 [In Ukrainian].
Kanestri, V.G., Kravchenko, A.B., Tishkevich, O.A., Golokhvastova, E.A, & Simonova, I.A. (2011). Khronicheskiy gepatit C u VICH-infitsirovannykh [Chronic hepatitis C in HIV-infected]. Epidemiologiya i infektsionnyye bolezni – Epidemiology and Infectious Diseases, 1, 56-57 [in Russian].
Kanestri, V.G. (2001). Kombinirovannaya protivovirusnaya terapiya khronicheskogo gepatita С u bolnykh VICH-infektsiyey [The combined antiviral therapy of a chronic hepatitis With at sick of a HIV-infection]. Candidate’s Extended abstract. Moscow: Izdatelskiy tsentr MGAPI [in Russian].
Eyster, M.E., Diamondstone, L.S., Lien, J.M., Ehmann, W.C., Quan, S., & Goedert, J.J. (2013). Natural history of Hepatitis C virus infection in multitransfiised hemophiliacs. Effect of coinfection with HIV. J. AIDS, 86, 602-610.
Lauer, G.M., & Walker, B.D. (2010). Medical progress: Hepatitis C virus infection. New Engl. J. Med., 385, 41-52.
Pokrovskiy, V.V. (2002). Klinicheskaya diagnostika VICH-infektsii: prakticheskoye rukovodstvo dlya studentov, vrachey-internov, klinicheskikh ordinatorov i vrachey vsekh spetsialnostey [Clinical diagnosis of HIV infection: a practical guide for students, interns, clinical residents and physicians of all specialties]. Moscow: GOU VUNMTS MZ [in Russian].
Eyster, M.E., Alter, H.J., Aledort, L.M., Quan, S., Hatzakis, A., & Goedert, J.J. (2001). Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann. Intern. Med., 145, 764-768.
Jaeckel, E., Cornberg, M., & Wedemeyer, H. (2011). German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med., 385, 1452-1457.
Vandelli, C., Renzo, F., Romano, L., Tisminetzky, S., Palma Michu, Stroffolini, T., Ventura, E., & Zanetti, A. (2014). Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am. J. Gastroenterol., 139 (6), 855-859.
Thomas, D., Astemborski, J., Rai, R., Anania, F.A., Schaeffer, M., Galai, N., ... Vlahov, D. (2010). The natural history of HCV-infection: host, viral, and environmental factors. JAMA, 324, 450-456.
Rice C.M. (2004). Molecular virology and pathogenesis of hepatitis C. San Francisco, California February 8-11, Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (CROI). San Francisco-California, Abstract 8.
Benhamou, Y., Bochet, M., Martino, V.P., Charlotte, F., Azria, F., Coutellier, A., ... Poynard, T. (2009). Liver fibrosis progression in human immunodeficiency virus and hepatitis С virus coinfected patients. The Multivirc Group. Hepatology, 70, 1054-1058.
Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J.A., García-Bengoechea, M., Hernández-Quero, J., … Lissen, E. (2007). Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an usually rapid progression to cirrhosis. J. Hepatol., 66, 1-5.
Núñez, M., & Soriano, V. (2015). Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. J. Infect. Dis., 231(1), 1-3.
Fultz, S.L., Chang, C.C.H., Sanderson, M., Eghtesad, B., Thai, N., Shakil, O., … Ragni, M.V. (2014). Survival in patients coinfected with HIV and hepatitis C in the HAART era. Bangkok June 11-16, 25-th International AIDS Conference. Bangkok, poster 3318.
Rosenthal, E., Poiree, M., Pradier, C., Perronne, C., Salmon-Ceron, D., Geffray, L., … Cacoub, P. (2013). Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2011 study). AIDS, 47(12), 1803-1809.
Tedaldi, E., Baker, R., Moorman, A., Barbarini, G., Moroni, M., & Basilico, C. (2013). Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART. Clin. Infect. Dis., 76, 363-367.
Pol, S., Lebray, P., & Vallet-Pichard, A. (2014). HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clinical Infectious Diseases, 78 (2), 65-72.
Lumbreras, B., Jarrin, I., Del, A.J., Kerr, T., Fischer, B., Krajden, M., … Tyndall, M.W. (2013). Impact of hepatitis С infection on long-term mortality of injecting drug users from 2000 to 2012: differences before and after HAART. AIDS, 48 (1), 111-116.
Yuditskiy, M.V., Shakhgildyan, V.I., Gruzdev, B.M., Filippov, P.G., Olshanskiy, A.Ya., Tyshkevich, O.A., … Vasilyeva, T.Ye. (2008). Spektr, osobennosti klinicheskogo techeniya, diagnostika opportunisticheskikh i soputstvuyushchikh zabolevaniy u VICH-infitsirovannykh bolnykh infektsionnogo statsionara g. Moskvy [Spectrum, features of the clinical course, diagnosis of opportunistic and concomitant diseases in HIV-infected patients of the infectious hospital in Moscow]. Terapevt. Arkhiv – Therapeutic Achieve, 11, 10-17 [in Russian].
Lincoln, D., Petoumenos, K., & Dore, G.J. (2013). HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Medicine, 44 (3), 241-249.
Stebbing, J., Water, L., Mandalia, S., Bower, M., Nelson, M., & Gazzard, B. (2015). Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defming events. Clin. Infect. Dis., 81 (6), 906-911.
Asten, L., & Prins, M. (2014). Infection with concurrent multiple hepatitis С virus genotypes is associated with faster HIV disease progression. AIDS, 58 (17), 2319-2324.
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, C., & Cacoub, A. (2012). Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS, 56(6), 813-828.
Den Brinker, M., Wit, F., Wertheim-van Dillen, P., Jurriaans, S., Weel, J., van Leeuwen, R., … Lange, J.M. (2010). Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS, 54, 2895-2902.
Kostenko, I.G., Sidorenko, Ye.V., & Gornostay M.V. (2015). K voprosu laboratornoy diagnostiki gepatita С [To the issue of laboratory diagnosis of hepatitis C]. [E-resource]. Retrieved from: http://hepatit.org.ua/diagnostika/k-voprosu-laboratornoy-diagnostiki-gepatita-s/ [in Russian].
Malyy, V.P., Gololobova, O.V., Lyadova, T.I., Boyko, V.V. (2013). Kliniko-diagnosticheskaya kharakteristika genotipirovaniya obligatno-gepatotropnykh virusov. Vliyaniye genotipov virusov na klinicheskiye proyavleniya i iskhody bolezni [Clinical and diagnostic characteristics of genotyping obligate-hepatotropic viruses. Influence of genotypes of viruses on the clinical manifestations and outcomes of the disease]. Aktualna infektolohiya, 1(1). [E-resource]. Retrieved from: http://www.mif-ua.com/archive/article_print/37335 [in Russian].
Saadeh, S., Cammell, G., Carey, W.D., Arey, C., Obair, Z., Ounossi, Y., … Asley E. (2011). The role of liver biopsy in chronic hepatitis C. Hepatology, 73(1), 196-200.
BMJ Best Practice. (2016). Hepatitis C. [E-resource]. Retrieved from: https://bestpractice.bmj.com/topics/uk-ua/128/pdf/128.pdf
EASL Recommendations on Treatment of Hepatitis C 2016. (2017). Journal of Hepatology, 66, 153-194.
American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. (September 2017). [E-resource]. Retrieved from: http://hcvguidelines.org/ (last accessed 26 September 2017).
Van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., … Janssen, H.L. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308, 2584-2593.
Kohli, A., Shaffer, A., Sherman, A., Kottilil S. (2014). Treatment of hepatitis C: a systematic review. JAMA, 312, 631-640.
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., … Marcellin, P. (2014). ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med., 370, 1889-1898.
Nakaz MOZ Ukrainy № 729 vid 18.07.2016 r. «Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Virusnyi hepatyt C u doroslykh» [Order of the Ministry of Health of Ukraine No. 729 dated July 18, 2016 «Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical aid. Viral hepatitis C in adults]. [E-resource]. Retrieved from: http://gt-medical.com.ua/wp-content/uploads/2016/07/2016_729_YKPMD_VGC.pdf [in Ukrainian].
Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., … Beumont-Mauviel, M. (2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, 384, 403-413.
Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T., … Diago, M. (2010). A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology, 139, 1593-1601.
Downloads
Published
Issue
Section
License
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
